pyc is news in asia

Phylogica accesses novel half-life extension tech

Singapore, Jan 14, 2011: Phylogica, an Australia-based drug discovery company, has entered an alliance with XL-protein, a German-based biotech company that specializes in extending the circulation half-life of biopharmaceuticals. Through this alliance, Phylogica gains access to a unique modification technology that strengthens the Companys Phylomer drug discovery platform.
XL-proteins PASylation technology was originally developed by a leading academic group at the prestigious Technical University of Munich (TUM). The technology utilizes a genetic technique to fuse a polymer of natural amino acids onto the relevant peptide or protein-based therapeutic, which slows the bodys clearance of the drug and prolongs the therapeutic effect.
Phylogica and XL-protein will initially collaborate on a pilot study to validate the technology in combination with one of Phylogicas Phylomer peptides targeting CD40 ligand from its in-house anti-inflammatory program. Under the terms of the agreement, Phylogica has an option to obtain an exclusive license to the PASylation technology for peptide-based products in relation to CD40 ligand and has rights of negotiation for a license to the technology for Phylomers that bind other targets.
It is anticipated that the plasma half-life of PASylated Phylomers will be significantly extended, making them more suitable for less frequent administration and at lower dose. Long acting Phylomers would be ideal for treating chronic indications, such as rheumatoid arthritis, coronary artery disease and inflammatory bowel disease, in which CD40 ligand has been implicated as a potential target.